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Nasopharyngeal carcinoma (NPC) is a rare head and neck neoplasm worldwide. It 
is common among the southern Chinese with significant geographical variation with 
the highest incidence being in Southeast Asia up to 6.4/100,000 males and 2.4/100,000 
females in these regions and the Epstein Barr virus (EBV) is associated closely with 
NPC. This disease has peculiarities in its etiopathogenesis, presentation, risk of nodal 
and distant metastasis, response to therapy and overall survival (OS) outcomes that 
stand out as compared to other head and neck cancer subsites. NPC is mainly treated 
by RT and is profoundly radiosensitive and radiotherapy treatment is the spine of 
treatment for all stages of NPC without far off metastases. Many advances in RT 
techniques and schedules are attempted to improve outcomes of the disease starting 
from intracavitary brachytherapy, intensity modulated RT to simultaneous modulated 
accelerated RT, all showing some promise with most significant benefit seen with addi-
tion of chemotherapy, especially in intermediate (Stage II) and advanced (Stage III, 
IVA, IVB) cases. At a time when modern radiation treatment like intensity-modulated 
radiotherapy (IMRT) are accomplishing great good local control, distant metastases 
are getting to be the transcendent design of treatment failure, particularly in patients 
with locally progressed illness. There are numerous results from clinical trials looking 
at combined radiation treatment (RT) and chemotherapy for NPC. Survival rates 
significantly differ between NPC patients according to stages of disease.
Keywords: nasopharyngeal carcinoma, epidemiology, risk factors, Epstein-Barr 
virus, clinical outcomes
1. Introduction
Nasopharyngeal carcinoma (NPC) is a rare disease and one of the most common 
types of malignancies that appear in the nasopharynx, which is the narrow tube 
passage behind the nasal cavity and one of the malignancies associated with the 
Epstein-Barr virus (EBV) and is considered one of the malignant and rare tumors 
in most parts of the world and is distinguished by distribution geographical and 
ethnic [1]. In southern China, it is one of the leading causes of death and morbidity. 
Notwithstanding the common burden of NPC in some endemic areas, the etiology 
and prevention of NPC is relatively unknown.
In 1978 the histopathological classification of nasopharyngeal carcinoma 
proposed by the World Health Organization was adopted, which divided tumors 
into three types. Type 1 was typical of squamous cell carcinoma, similar to the 
rest of the upper gastrointestinal tract. The second type included non-keratinized 
squamous cell carcinoma and the third type was undifferentiated carcinoma. In 
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epidemiological research this classification is more applicable and has been shown 
to have a predictive effect. Undifferentiated carcinomas have a higher rate of local-
ized tumor control during treatment and a higher rate of distant metastases.
Among cancers of the head and neck, nasopharyngeal carcinoma is one of the 
most common type of cancers [2]. It is also a virulent disease that has been accounted 
for to occur in many parts of the world with a uniform incidence rate for age and sex, 
one of every 100,000 every year [3]. This malignant growth has an unequal geo-
graphical distribution with the incidence rate on one continent higher than on other 
continents, which was very high in Asia (80%) and 10% in Africa. The rest 10% have 
been accounted for somewhere in the world, and Southeast Asian nations represent 
67% of cancer burden worldwide. In addition to geographical differences, some 
ethnic gatherings might be in danger of creating nasopharyngeal malignancy. For 
example: Bidayuh on Borneo Island, Inuit in the Arctic and Nagas in Northern India, 
with an old norm of more than 16 for every 100,000 every year for men [4].
In non endemic regions, during last 50 years, incidence of poorly or undiffer-
entiated NPC raised [5, 6]. However, this was supposed to be mostly related to the 
increase of migration flows towards these areas from endemic regions rather than 
an augmented exposure of residents to risk factors for NPC development. Indeed, in 
low incidence countries, the risk of development of NPC in immigrants is estimated 
to be around 30-fold greater than in residents. The association between Epstein-
Barr virus (EBV) and nasopharyngeal carcinoma (NPC), has marked geographic 
and ethnic differences in its incidence [7]. The Over population in Asia, responsible 
for the increased rate of death by NPC, from 45,000 (in 1990) to 65,000 (in 2010) 
[8]. In Africa and some regions of East Asia, the nasopharyngeal carcinoma is more 
common and the incidence rate is generally lower from 1 for every 100,000 persons 
[9]. However, there are around 25 per 100,000 people in southern China, which 
is 18% of all cancers [10]. In Asia, NPC occurs in all ages but more common in the 
middle-aged population, although there is a high incidence of cases in children in 
Africa. A study on NPC and EBV showed a particular association between natural 
factors such as viral antibody factors, genetic factors and diet [11].
NPC is one of the highly invasive neoplasia and malignancies that spread early to 
regional lymph nodes [12]. Radiation therapy (RT) is also seen as an essential sup-
portive treatment for management because of the sensitivity of the radiation to the 
type of disease. In advanced stages of disease, chemotherapy (CT) has been used for 
more than 20 years and some studies confirmed the benefit of chemoradiotherapy 
(CRT) in stages II to IV [13].
2. Global trends
In 2012, 86,691 nasopharynx cancer cases occurred in the world and 50,831 
nasopharynx death cases, and in 2018 there were around 130,000 accidents and 
more than 73,000 deaths from nasopharyngeal carcinoma (NPC) worldwide [14]. 
The global NPC incidence and mortality distribution reported very high rates 
(more than 20-30/100,000 men and 10/100,000 women) in Southeast Asia [15], 
some regions of southern China, [16], Singapore, [17] Hong Kong, [18] Taiwan, 
[19] Selected Chinese immigrants (mainly to North America), [20, 21] and the 
Middle East [22]. In most of the western countries, Latin America and Japan that 
are non-endemic areas, the incidence rate of NPC showed less than 1/100,000 [23]. 
Recent studies have shown the incidence of NPC is high in cities like Zhongshan, 
Zhuhai, Hong Kong, and Jiangmen (standard age: 12.8-25 per 100,000 per year for 
men) in southern China [24–26] (Figure 1).
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3. Age and gender
The incidence of nasopharyngeal carcinoma increases two to three times more 
frequently in men than in women [27]. Male predominance in the population is a 
common trait among NPC patients. Male dominance in the incidence of NPC can 
be partly explained by biological or gender differences or different lifestyles in the 
prevalence of some environmental risk factors, such as smoking and hazardous 
occupational exposure [28].
The nasopharyngeal carcinoma incidence in most low-risk groups is consistent 
with increasing age [29]. On the other hand, in the 50 to 59 age group, the incidence 
of NPC increases because these groups are more susceptible, and then decreases 
[30], which is related to the exposure of these groups to carcinogens in the early life 
stages [31].
It can take several decades for nasopharyngeal carcinoma to develop malignant 
cells. After that, the signs appear. Therefore, the outcome of carcinogens exposure 
in early life will have a sizeable effect on the development of this cancer [28].
4. Risk factors
Since the first case of this malignancy was recorded in 1901 [32], the etiology 
of the NPC has not been identified as a mystery. Risk factors for NPC, most com-
monly in men [33], include a family history of NPC, EBV infection, low intake 
of fresh vegetables and fruits, high consumption of salt-canned fish, smoking 
and Cantonese races [34]. On the other side, a reduced risk may be associated 
with a history of infectious mononucleosis (IM) and HLA genotypes [35]. Other 
potential risk factors are the genetic polymorphism in glutathione S-transferase 
M1 (GSTM1), GSTT1, cytochrome P450 2E1 (CYP2E1) and CYP2A6[36], possibly 
high consumption of other preserved foods [37, 38] and the history of chronic 
respiratory diseases. The exposures to dust and formaldehyde, nickel exposure and 
consumption of herbal medicine are less established risk factors [39].
Figure 1. 
Incidence of Nasopharyngeal carcinoma (2012) (GLOBOCAN 2012) [26].
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4.1 Epstein-Barr virus (EBV)
The relationship of NPC to EBV-associated is known and proven, and EBV 
infection is one of the common infectious agents in the population. This relation-
ship concluded the hypothesis that an EBV subtype of NPC plays a role in increas-
ing the incidence of NPC in the epidemic regions. The association between EBV 
infection and nasopharyngeal carcinoma is very strong and has been demonstrated 
in several studies [40].
In the nucleus of malignant cells there are approximately 30 copies of the EBV 
gene. Most versions refer to the presence of "small circular chromosomes" called 
episomes. In some cases, these episomes are adjacent to the viral DNA releases. 
The use of serological and virological tests is recommended to diagnose and study 
the populations at risk. In areas with an increased incidence of nasopharyngeal 
carcinoma, high levels of IgA antibodies with EBV capsid antigen and Epstein-Barr 
nuclear antigen are considered to be a valuable screening test or the new prediction 
model combining VCA/IgA and EBNA1/IgA which will improve diagnosis of NPC 
and could identify high-risk population [41].
4.2 Familial history and genetic susceptibility
It is known that families with a history of cancer, particularly nasopharyngeal 
carcinoma, are 4 to 10 times more likely to develop nasopharyngeal carcinoma. Some 
studies have reported that familial clustering is stable in areas with a high incidence of 
NPC [42] and in areas with low to moderate incidence [43]. In southern China, where 
NPC is endemic, more than 5% reported NPC with a positive family history of NPC in 
cases with first-degree family history [44]. Evidence and studies of previous case con-
trol studies have shown indifferent populations that the odds ratios for people between 
2 and 20 with history of NPC and history of first-degree family were compared to 
people without such a medical history [45]. This size of association is among the high-
est in any malignant disease. In nasopharyngeal carcinoma the genetic research focuses 
on genes of human leukocyte antigen. Where it occurred in subjects with presence of 
EBV and weak HLA allele, the antigens likely increased the risk of developing naso-
pharyngeal carcinoma. The development of NPC less likely in people with the presence 
of EBV associated with strong HLA allele. In etiology of NPC, it is possible that genet-
ics and environmental exposure play a common role. Four correlation studies with 
susceptibility sites of 4p15.1_q12, 6p2153, 3p21.31e21.2 and 5p13 in NPC families of a 
single major susceptibility gene were observed and reported, supported by the results 
of NPC complex family segregation analysis, indicating that this the pathogens of NPC 
includes the interaction of many environmental and genetic factors [46, 47].
The genetic factor is one of the notable features of the race distribution in the 
cantonese population. The shared roles of environmental factors, lifestyle and 
genetics should not be ignored. Whether familial NPC cases differ significantly 
from sporadic cases in terms of clinical features (such as histopathology, stage 
of disease, and prognosis), gender, race, age, EBV sera, genetic risk factors, and 
environmental risk factors [48].
4.3 Exposure to carcinogens
4.3.1 Salt-preserved foods and fish
Several studies have reported that eating fish with salt is considered a risk factor 
for cancer. For the Chinese, the relative risk of developing pharyngeal cancer is 
lower among weekly consumers than those who use very little or no salt-canned 
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fish. Overall it was about 1.4 to 3.2 [36, 37]. The relative risks are between 1.8 and 7.5 
for those who consume daily [49, 50]. The risk of developing nasopharyngeal carci-
noma is higher with other canning foods such as fruits, vegetables, eggs and meat in 
Southeast Asia, Southern China, the Middle East, North Africa and the Arctic [51]. 
This preservative food is also implicated in people found in low-incidence areas of 
northern China and the United States [52].
4.3.2 Exposure to smoking and occupational products
The direct relationship between nasopharyngeal carcinoma and smoking was 
confirmed by reports that people who had smoked cigarettes for ten years or more 
were more likely to develop NPC [53]. Several studies have confirmed that cigarette 
smoking is linked to nasopharyngeal carcinoma. The relationship pattern between 
the risk of developing nasopharyngeal carcinoma and smoking depends on the 
dose, especially in well-differentiated nasopharyngeal carcinoma [54]. Lin et al. 
[55] compared the surroundings of NPC patient with those of neighboring controls 
in Taiwan and found that cigarettes were smoking and working in poorly ventilated 
rooms was closely related to the NPC.
Another study found that long-term cigarette smoking was linked to the NPC, 
but only to a minor extent exposure to cigarette smoke through passive exposure to 
smoking and alcohol consumption is not associated with a disease risk [56].
4.3.3 Oral hygiene
There is a connection between poor oral hygiene in the elderly and cancers of the 
head, neck, esophagus and stomach [57]. In NPC, periodontal disease can increase 
recurrent inflammation and thus increase possibility of developing NPC as the 
inflammatory response may be on the way to promoting carcinogenesis, Zhiwei Liu 
et al 2016 suggested poor oral health may increase risk of NPC [58]. In addition, 
When more teeth are lost, the bacterial load also increases. Some types of bacteria 
are involved in the increased production of nitrosamine, which is thought to be 
carcinogenic and has been linked to the development of NPC. Poor oral hygiene can 
also increase the risk of NPC by EBV stimulation and proliferation, as evidenced by 
higher viral loads in people with periodontitis more than others [59].
4.3.4 Other risk factors
The relationship between alcohol consumption and nasopharyngeal carcinoma 
has been documented in complicated ways. Several studies have documented that 
there is no clear confirmation of a relationship between the risk of nasopharyngeal 
carcinoma and alcohol consumption [60]. Other studies confirmed the relation 
between nasopharyngeal carcinoma and the exposure to wood dust. Several studies 
have shown an increased risk of developing nasopharyngeal carcinoma after expo-
sure to formaldehyde [61]. Exposure to other chemicals or stimuli such as smoke, 
steam, cotton dust, chemicals, flammable products, or solvents such as chlorophe-
nol and phenoxy acid increases the risk of developing nasopharyngeal carcinoma 
[62]. An association between nasal cavity and sinus cancer and the textile work 
has also been reported [63]. In addition, several other non-dietary risk factors 
for nasopharyngeal carcinoma have been included [64]. It has been reported that 
occupational exposure to combustion products and cotton dust is independently 
related to NPC risk. The risk of developing NPC also increases through occupational 
exposure to formaldehyde and not through exposure to wood dust [65]. However, 
this association appears to be specific to squamous cell carcinoma. In addition, 
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eating canned foods has been linked to NPC at a young age and risk in all popula-
tion groups [33]. Studies and data on inhalation of different types of smoke/fumes/
dust show that inhalants can play an important role, although they can secondary as 
a catalyst is the high incidence of NPC in various geographic regions of the world.
5. Treatment
5.1 Radiation therapy
Radiation therapy is the first type of cancer treatment method for non-invasive 
nasopharyngeal carcinoma (NPC) due to anatomical limitations and high sensitiv-
ity to radiation. One of the treatment method is with two-dimensional radiation 
therapy (2DRT), which has been converted to 3D compliant radiation therapy, 
and particularly highly modified radiation therapy (IMRT), is an important step 
forward in the treatment of NPC.
IMRT use was first reported in 2000 by the University of California at San 
Francisco. The results with 100% local control and a 4-year operating system are a 
dramatic 94%.
The second phase of II trails 0225 by the Radiation Oncology Group then 
showed that it is possible to transfer IMRT to a multi-institutional setting [66]. 
Three comparative randomized trials studies of IMRT and 2DRT have been applied. 
Chen et al. The studies confirmed a significant improvement in the therapeutic 
ratio by IMRT: The use of IMRT in patients with NPC demonstrated an improved 
terminal therapeutic ratio compared to 2DRT over a follow-up period of more than 
10 years with significant improvement in OS, FFS, and L-FFS [67].
5.2 Adjuvant and neoadjuvant chemotherapy
While chemotherapy given concurrently with RT offers consistent benefits, the 
adjuvant chemotherapy role after alternative chemoradiotherapy is uncertain. The 
chemotherapy induction attempts for cases with local metastasis which include 
concomitant chemotherapy and radiation therapy, followed by adjuvant chemo-
therapy, in which an increased rate of NPC relapse in remote locations was observed 
in a large proportion of patients. These studies have shown the usefulness of this 
strategy for the OS. The administration of adjuvant chemotherapy was associated 
with significant toxicity, with 25-45% of the patients exhibiting high grade toxici-
ties [68]. In addition, some research studies evaluating chemoradiotherapy proto-
cols without adjuvant chemotherapy which provided similar results to studies using 
simultaneous and adjuvant chemotherapy, raising questions about the actual results 
and benefits of adjuvant chemotherapy for NPC control [69].
In theory, novel chemotherapy can prevent micrometastases earlier and also 
facilitate the mapping of RT by decreasing local metastasis, especially in large 
tumors. So far, phase III studies on novel adjuvant chemotherapy with post-
radiation therapy alone have proven no difference in OS compared to RT [70]. An 
up to date meta-analysis of MAC-NPC contained data from a number of induction 
chemotherapy studies and showed statistically excellent results in survival with-
out disease progression, but not in OS [71]. Increased cases with leukopenia and 
neutropenia rates observed during the CRT period [72]. This confirms the primary 
interest in the new induction/adjuvant approach, which could interfere with the 
delivery of chemotherapy with effective doses and/or radiation therapy during 
the period of CRT or increased toxicity and outweigh the potential benefits of the 
induction-based approach.
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5.3 Treatment in advanced NPC
Although chemotherapy concurrently with radiation has resulted in many 
improvements with significant outcomes in NPC patients, and improve survival in 
locally advanced NPC over 5 years in 50-70%. A large proportion of patients have 
relapsed either locally or in distant sites, or both. Adding more chemotherapy drugs 
to available protocols is not a viable approach as CRT already exhibits significant 
toxicity. Instead, more research aims to identify the possibility of recurrence or 
relapse before treatment or at the end of the CRT assessment, who can focus on 
additional research methods. Second, the use of personalized target therapy in 
conjunction with radiation therapy or chemotherapy is assessed.
In NPC patients, the epidermal growth factor receptor (EGFR) overexpression is 
80% or more and associated with lower survival results [73]. Adding of cetuximab, 
a monoclonal chimeric antibody in patients with squamous cell carcinoma of the 
head and neck against EGFR in conjunction with RT of HNSCC in locally advanced 
stages, which reported improvement and significant in OS in comparison to RT 
alone [74]. The evaluation of cetuximab in concurrent with radiation therapy in 
comparison to standard CRT in NPC patients has not proven to be more effective 
due to the association with increased rates of mucositis [75]. The combination of 
IMRT radiation therapy and weekly cisplatin with cetuximab was more effective in 
patients in advanced stages [76].
5.4 Palliative chemotherapy for metastasis and relapses NPC
Palliative chemotherapy is very important and plays role in control of disease 
and keep patients in good conditions as well as in extending survival of patients 
with NPC metastases as NPC is very sensitive to chemotherapy cancer. Standard 
treatment includes chemotherapy with platinum in combination with other drugs 
such as 5-FU with cisplatin/carboplatin and paclitaxel with gemcitabine. Patients 
treated for long time with platinum chemotherapy, can achieve a significant 
response with rates of up to 80% and an average survival rate of 12 to 18 months 
[77]. There is a significant correlation between higher response rates with a com-
bination therapy regimen than monotherapy, and platinum is a good treatment, 
but it is not the main criterion or standard treatment. Regardless of the treatment 
regimen chosen for the first line, the average progression time after 7 to 10 months 
remains relatively constant [78, 79]; This is related to the development of platinum 
resistance. The response rates for a triple therapy with paclitaxel/carboplatin/
gemcitabine are impressive and close to 80%. However, the average response time is 
about 8 months, similar to two drug regimens [80].
5.5 Novel therapies: molecular-targeted agents
The past 10 years have seen the development of new treatments for NPC and 
this has been somewhat simultaneous with the development of treatment for other 
cancers. Little progress has been made in recent years beyond the usual cytotoxic 
approaches. EGFR-mediated signaling pathways inhibited by the molecular fac-
tors that lead to inhibition of cell growth and cell apoptosis which include tyrosine 
kinase inhibitors, for example gefitinib and monoclonal antibodies [81].
In a number of centers, Ueda and colleagues [82] investigating a combination 
treatment of carboplatin, paclitaxel and cetuximab in patients with metastatic or 
recurrent or with repeated platinum-resistant NPC showed good survival benefit, 
an overall response rate reach to 64 % and a median OS of 29.1 months with fol-
low up for 30 months. The treatment with gefitinib had little response rates in 
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metastatic and recurrent NPC treated previously with platinum-based chemo-
therapy. The symptomatic improvement and disease stabilization were observed in 
some cases [83].
Multikinase inhibitors target tyrosine kinases such as fibroblast growth factor 
receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and vascular 
endothelial growth factor receptor (VEGFR) and drugs such as pazopanib (VEGFR, 
PDGFR, FGFR, c-KIT), sorafenib (VEGFR, PDGFR, Raf kinases), and sunitinib 
(PDGFR, VEGFR, C-KIT), have been evaluated in NPC [84, 85].
6. Mortality and survival
6.1 Mortality of NPC
Global mortality rates of NPCestimated 51,000 deaths in 2012 among females 
and males were 0.04 per10, 000 and 0.1 per 10,000, respectively.
The mortality rate were high in Southeast Asia, East Asia, East Africa North 
Africa and Micronesia. Nasopharyngeal carcinoma is the native cancer of Southeast 
Asia and the countries with the highest mortality were Malaysia, Singapore, 
Indonesia, Vietnam, and Brunei [26] (Figure 2).
6.2 Survival patterns of NPC
Early diagnosed NPC patients respond very well to radiation, and this treat-
ment shows promise. Radiation therapy is the strategy treatment for treating NPC. 
However, approximately 70% of stage III or IV NPC patients are exposed to a local 
and/or regional condition of distant metastases or recurrences after radiation 
therapy [86]. Treatment with combination of chemotherapy and radiation therapy 
often required for advanced NPC [87].
Studies have shown that intensity modulated radiation therapy (IMRT) often 
produces larger radiation dose distributions corresponding to improved tumor 
exposure and allows for lower doses of normal tissue for a variety of cancers that 
Figure 2. 
Mortality rate of nasopharyngeal carcinoma in Asia in 2012 (GLOBOCAN 2012) [26].
9




Faculty of Medicine and Health Sciences, University of Aden, Aden, Yemen
*Address all correspondence to: drgamal2000@yahoo.com
occur in the head and neck area [88]. In addition, the prognosis of NPC associated 
with many factors are, including age, sex, TNM stage, histology, radiation dose, 
leukopenia and anemia, and the type of combined chemotherapy [89]. Therefore, 
minimizing the risk of late complication and distant metastasis and maximizing the 
local control should be the key objects in designing future treatment.
7. Conclusions
Nasopharyngeal carcinoma is a rare head and neck malignancy and the native 
malignancy of Southeast Asia. Nasopharyngeal carcinoma (NPC), predominantly 
associated with Epstein-Barr virus (EBV), is characterized by remarkable geo-
graphical and racial differences in its incidence. The incidence of NPC is generally 
less than 1 per 100,000 individuals; however, in southern China it is around 25 per 
100,000 individuals, accounting for 18% of all cancers. Epidemiological studies 
over the past few decades have shown a gradual decrease in incidence and a marked 
decrease in NPC mortality. However, the rise in population in Asia has increased the 
number of deaths caused by NPCs from 45,000 in 1990 to 65,000 in 2010.
The development of image diagnostic techniques and introducing chemoradio-
therapy (chemo-IMRT) followed by adjuvant chemotherapy resulted in excellent 
locoregional control and increased survival rates among patients with NPC.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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